Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|October 18, 2014
Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre studyUwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2015
Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literatureR Mössner, L Zimmer, C Berking, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2022
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Data in Brief|November 25, 2022
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseasesThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|June 7, 2014
[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]R Gutzmer, J C Hassel, K C Kähler, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2016
[Risk stratification and follow-up assessment of patients with pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]H H Leuchte, H Ten Freyhaus, H Gall, et al.
Cancers|March 14, 2026
Mycophenolate Mofetil for Treatment of Ipilimumab-Induced Colitis in Patients with Metastatic MelanomaChristina Naoum, Julia K Winkler, Pawel Majenka, et al.
Plos One|May 26, 2018
Willingness to pay for a cure of low-risk melanoma patients in GermanyMatthias Augustin, Christine Blome, Andrea Forschner, et al.
Journal of Internal Medicine|January 11, 2021
Telehealth mitigates COPD disease progression compared to standard of care: a randomized controlled crossover trialF Rassouli, A Germann, F Baty, et al.
Oncotarget|June 15, 2018
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physiciansKatharina C Kähler, Christine Blome, Andrea Forschner, et al.
Pageof 11